Scott Alexander summarizes and responds to comments on his post about semaglutide, covering corrections, additional information, and user experiences with the weight loss drug.

Scott Alexander analyzes the economic and societal implications of semaglutide, a new effective weight loss drug, and its potential to reshape obesity treatment.

Scott Alexander discusses potential Trump administration health-related appointments, focusing on FDA commissioner candidates Jim O'Neill and Balaji Srinivasan, and their potential to implement beneficial reforms.

Scott Alexander argues that the EpiPen price hike is due to over-regulation and cronyism in the pharmaceutical industry, not lack of regulation as suggested by Vox.

The post examines three major issues with generic medications: barriers to market entry, problematic FDA initiatives, and inconsistent pricing across pharmacies.